Neumora Therapeutics reported a net loss of $34.4 million for the third quarter of 2026, an improvement from the $56.8 million loss in the prior year period. The company's cash and cash equivalents decreased significantly to $85.7 million as of September 30, 2026, compared to $182.5 million at the end of 2025, while total stockholders' equity fell to $18.6 million.
Neumora Therapeutics reported third quarter 2026 financial results and provided a pipeline update, including the submission of an IND application for NMRA-215 in obesity. The company reported a cash position of $85.7 million and noted that it will require substantial additional funding to continue operations and complete product development.
Neumora Therapeutics received a deficiency notice from Nasdaq for failing to maintain the $1.00 minimum bid price requirement for its common stock. The company has 180 calendar days, until April 26, 2027, to regain compliance by having its stock close at $1.00 or higher for at least ten consecutive business days.